Serious risks identified in FDA labeling: FDA labeling for approved GLP-1 and GLP-1/GIP medications includes warnings about risk of pancreatitis, gallbladder disease, acute kidney injury (often related to dehydration from severe gastrointestinal effects), hypoglycemia (particularly when combined with insulin or sulfonylureas), diabetic retinopathy complications in patients with type 2 diabetes, and serious hypersensitivity reactions
Some of these products have not undergone sufficient human clinical trials and may cause significant harm
Several factors can contribute to this calorie imbalance, including: Dr
If you take medication or have underlying health conditions, checking with a healthcare professional first is a good idea
When patients understand the connection between metabolic health and reproductive function, they are more likely to stay engaged in treatment
The usual dose has no effect in some individuals, causes serious toxicity in others, and produces an optimal effect in a few